According to a press release issued by the Hyderabad-based vaccine maker, Bharat Biotech owns the rights to distribute the vaccine in all markets except the US, Japan and Europe.

Bharat Biotech On Wednesday signed a licensing agreement with Washington University School of Medicine in St Louis for a novel “chimp-adenovirus” (Chimpanzee adenovirus), single dose intranasal vaccine for COVID-19.

According to a press release issued by the city-based vaccine maker, Bharat Biotech owns the rights to distribute the vaccine in all markets except the US, Japan and Europe.

Also read: COVID-19 vaccine | Bharat Biotech starts human trial at PGI Rohtak

While the Phase I trials will take place in St Louis University’s Vaccine and Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley here, it said.

“Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines.

Also read: COVID-19: Vaccine strategy ready, says Harsh Vardhan

“It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world,” Chairman and Managing Director of Bharat Biotech, Dr Krishna Ella said.

The company envisions to scale this vaccine to one billion doses, translating to an equal number of individuals vaccinated receiving a single-dose regimen.

An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive, it said.

Director of Biologic Therapeutics Center and Professor of Radiation Oncology atWashington University School of Medicine and Precision Virologics Interim CEO, Dr David T Curiel said,”The ability to accomplish effective immunization with a single nasal dose is a major advantage, offering broader reach and easier administration.

“An effective nasal dose not only protect against COVID- 19, but it also prevents the spread of the disease by offering another kind of immunity that occurs primarily in the cells that line the nose and throat.

“Most other vaccine candidates currently under development can’t do that”, the company said.

This vaccine expands BBs portfolio of vaccines that are currently being developed and are in various stages of clinical development including Covaxin which is currently in Phase II human clinical trials in India, it said.

Show Less Plan

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Faster pages

Move smoothly between articles as our pages load instantly.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Personalised recommendations

A select list of articles that match your interests and tastes.

Briefing

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.



Source link

Posts You May Love to Read !!

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *